Robert Azelby
2016
In 2016, Robert Azelby earned a total compensation of $1.9M as Executive Vice President, Chief Commercial Officer at Juno Therapeutics, a 81% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $132,800 |
|---|---|
| Option Awards | $643,532 |
| Salary | $409,413 |
| Stock Awards | $252,900 |
| Other | $473,580 |
| Total | $1,912,225 |
Azelby received $643.5K in option awards, accounting for 34% of the total pay in 2016.
Azelby also received $132.8K in non-equity incentive plan, $409.4K in salary, $252.9K in stock awards and $473.6K in other compensation.
Rankings
In 2016, Robert Azelby's compensation ranked 5,090th out of 14,075 executives tracked by ExecPay. In other words, Azelby earned more than 63.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,090 out of 14,075 | 64th |
Division Manufacturing | 1,815 out of 5,489 | 67th |
Major group Chemicals And Allied Products | 577 out of 1,895 | 70th |
Industry group Drugs | 432 out of 1,538 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 74 out of 279 | 74th |
Source: SEC filing on April 21, 2017.
Azelby's colleagues
We found four more compensation records of executives who worked with Robert Azelby at Juno Therapeutics in 2016.